Hyperion DeFi Management

Management criteria checks 0/4

Hyperion DeFi's CEO is Hyunsu Jung, appointed in Jun 2025, has a tenure of less than a year. directly owns 21.55% of the company’s shares, worth $7.52M. The average tenure of the management team and the board of directors is 0.6 years and 2.9 years respectively.

Key information

Hyunsu Jung

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	21.6%
Management average tenure	less than a year
Board average tenure	2.9yrs

Recent management updates

Recent updates

CEO

Hyunsu Jung (29 yo)

less than a year

Tenure

Mr. Hyunsu Jung is Chief Investment Officer & Director of Hyperion DeFi, Inc. (formerly known as Eyenovia, Inc.) from June 17, 2025 and serves as its Interim Chief Executive Officer since 2025. Prior to th...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Hyunsu Jung	CEO, Chief Investment Officer & Director	less than a year	no data	21.55% $ 7.5m
David Knox	Chief Financial Officer	less than a year	no data	no data
Norbert Lowe	Senior Vice President of Commercial Operations	1.8yrs	no data	no data
Enrico Brambilla	Senior Vice President of R&D	less than a year	no data	no data
Alexander Lobo	Investor Contact	no data	no data	no data

0.6yrs

Average Tenure

Experienced Management: HYPD's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Hyunsu Jung	CEO, Chief Investment Officer & Director	less than a year	no data	21.55% $ 7.5m
Michael Geltzeiler	Independent Director	2yrs	US$140.00k	0.12% $ 40.2k
Robert Weinreb	Member of Scientific Advisory Board	no data	no data	no data
Ellen Strahlman	Independent Director	3.3yrs	US$145.00k	0.096% $ 33.6k
James Tsai	Member of Scientific Advisory Board	no data	no data	no data
Pamela Gallin	Member of Scientific Advisory Board	no data	no data	no data
Jason Jones	Member of Scientific Advisory Board	2.9yrs	no data	no data
Mark Bullimore	Member of Scientific Advisory Board	5.9yrs	no data	no data
April Jasper	Member of Scientific Advisory Board	5.9yrs	no data	no data
Rachel Jacobson	Independent Director	3.8yrs	US$133.75k	0.091% $ 31.6k
Francis Mah	Scientific Advisory Board Member	2.9yrs	no data	no data
Nathan Radcliffe	Member of Scientific Advisory Board	2.8yrs	no data	no data

2.9yrs

Average Tenure

58.5yo

Average Age

Experienced Board: HYPD's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/17 18:16
End of Day Share Price	2025/11/14 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hyperion DeFi, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Kemp Dolliver	Brookline Capital Markets
Timothy Chiang	Northland Capital Markets
Esther Rajavelu	Oppenheimer & Co. Inc.

Hyperion DeFi Management

Management criteria checks 0/4

Key information

Recent management updates

Hyperion Defi, Inc. Announces Appointment of David Knox as Chief Financial Officer, Effective September 29, 2025

Hyperion Defi, Inc. Announces CEO Changes

Hyperion DeFi, Inc., Annual General Meeting, Aug 18, 2025

Eyenovia, Inc. Announces Chief Financial Officer Changes

Eyenovia, Inc., Annual General Meeting, Jun 12, 2024

High number of new directors

Recent updates

Hyperion DeFi, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Hyperion Defi, Inc. Reports Unaudited Impairment Charges for the Third Quarter Ended September 30, 2025

Hyperion DeFi, Inc. to Report Q3, 2025 Results on Nov 13, 2025

Hyperion Defi, Inc. Announces Appointment of David Knox as Chief Financial Officer, Effective September 29, 2025

Hyperion Defi, Inc. Announces CEO Changes

Hyperion DeFi, Inc. Regains Compliance with Nasdaq Listing Requirements

Hyperion DeFi, Inc., Annual General Meeting, Aug 18, 2025

Eyenovia, Inc. announced that it has received $50 million in funding

Eyenovia, Inc. announced that it expects to receive $50 million in funding

Eyenovia, Inc. announced delayed 10-Q filing

Eyenovia Receives A Notice from the Staff of the Nasdaq Stock Market Regarding Minimum Equity Requirement

Eyenovia, Inc. Provides Development Update on Optejet User Filled Device (UFD)

Eyenovia, Inc. announced delayed annual 10-K filing

Betaliq, Inc. entered into a non-binding letter of intent to acquire Eyenovia, Inc. (NasdaqCM:EYEN) in a reverse merger transaction.

Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements

Eyenovia, Inc. Announces Progress on Next-Generation User-Filled Optejet Dispensing Device

Eyenovia Announces 1-for-80 Reverse Stock Split to Regain Compliance with Bid Price Requirement

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $33.586557 million.

Nasdaq Determines to Delist Eyenovia's Securities

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $1.3 million.

New minor risk - Profitability

New major risk - Market cap size

Eyenovia, Inc. Provides Update on Phase 3 CHAPERONE Study

Eyenovia, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Eyenovia, Inc. Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $4 million.

Eyenovia, Inc. Receives A Letter from the Staff of the Nasdaq Stock Market Regarding Bid Price Requirement

Eyenovia, Inc. Announces Chief Financial Officer Changes

Eyenovia, Inc. has completed a Follow-on Equity Offering in the amount of $5.14 million.

Eyenovia, Inc. has filed a Follow-on Equity Offering.

New major risk - Financial position

Consensus revenue estimates decrease by 47%

Price target decreased by 11% to US$8.33

Eyenovia, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Eyenovia Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Consensus revenue estimates decrease by 32%, EPS upgraded

Eyenovia, Inc. to Report Q1, 2024 Results on May 15, 2024

Eyenovia, Inc., Annual General Meeting, Jun 12, 2024

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension

New major risk - Share price stability

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 27%

Consensus revenue estimates increase by 32%

Eyenovia, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Price target decreased by 8.6% to US$10.67

Consensus revenue estimates increase by 33%

Consensus revenue estimates increase by 33%

Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 54%

New minor risk - Share price stability

High number of new directors

Eyenovia, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?

Eyenovia, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?

Insider recently bought US$234k worth of stock

Eyenovia, Inc., Annual General Meeting, Jun 27, 2023

Eyenovia, Inc. Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis

Eyenovia, Inc. to Report Q1, 2023 Results on May 11, 2023

Co-Founder recently sold US$300k worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

CEO

Leadership Team